CN111315737B - 经砜吡啶烷基酰胺取代的杂芳基化合物 - Google Patents

经砜吡啶烷基酰胺取代的杂芳基化合物 Download PDF

Info

Publication number
CN111315737B
CN111315737B CN201880072389.7A CN201880072389A CN111315737B CN 111315737 B CN111315737 B CN 111315737B CN 201880072389 A CN201880072389 A CN 201880072389A CN 111315737 B CN111315737 B CN 111315737B
Authority
CN
China
Prior art keywords
amino
mmol
carboxamide
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072389.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315737A (zh
Inventor
刘春健
杨光
肖自力
陈岭
R·M·莫斯林
J·S·托克斯基
D·S·韦恩斯坦
S·T·沃布莱斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN111315737A publication Critical patent/CN111315737A/zh
Application granted granted Critical
Publication of CN111315737B publication Critical patent/CN111315737B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880072389.7A 2017-11-21 2018-11-19 经砜吡啶烷基酰胺取代的杂芳基化合物 Active CN111315737B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589165P 2017-11-21 2017-11-21
US62/589,165 2017-11-21
PCT/US2018/061726 WO2019103952A1 (en) 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Publications (2)

Publication Number Publication Date
CN111315737A CN111315737A (zh) 2020-06-19
CN111315737B true CN111315737B (zh) 2024-06-18

Family

ID=65036887

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072389.7A Active CN111315737B (zh) 2017-11-21 2018-11-19 经砜吡啶烷基酰胺取代的杂芳基化合物

Country Status (20)

Country Link
US (4) US11021462B2 (https=)
EP (1) EP3713930A1 (https=)
JP (2) JP7258903B2 (https=)
KR (1) KR102702228B1 (https=)
CN (1) CN111315737B (https=)
AR (1) AR113895A1 (https=)
AU (3) AU2018371010C1 (https=)
BR (1) BR112020009606A2 (https=)
CA (1) CA3083122A1 (https=)
CL (1) CL2020001338A1 (https=)
CO (1) CO2020006139A2 (https=)
EA (1) EA202091269A1 (https=)
IL (1) IL274816B2 (https=)
MX (1) MX2020005210A (https=)
MY (1) MY202167A (https=)
PE (1) PE20211461A1 (https=)
SG (1) SG11202004592TA (https=)
TW (1) TWI776994B (https=)
WO (1) WO2019103952A1 (https=)
ZA (1) ZA202003717B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005210A (es) * 2017-11-21 2020-08-20 Bristol Myers Squibb Co Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona.
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12428395B2 (en) 2019-08-01 2025-09-30 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
WO2022135430A1 (en) * 2020-12-22 2022-06-30 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CN114805438A (zh) * 2021-01-18 2022-07-29 正大天晴药业集团股份有限公司 含磷酰基的tyk2抑制剂化合物
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
US20240226106A1 (en) * 2021-03-17 2024-07-11 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
CN115141149A (zh) * 2021-03-30 2022-10-04 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
EP4448514A4 (en) 2021-12-16 2025-10-29 Lynk Pharmaceuticals Co Ltd TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN117263913A (zh) * 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
CN120661462A (zh) * 2022-06-20 2025-09-19 益方生物科技(上海)股份有限公司 药物组合物及其用途
WO2024125651A1 (zh) * 2022-12-16 2024-06-20 津药生物科技(天津)有限公司 新型含杂环取代的丙烯酸衍生物及其用途
WO2024217515A1 (zh) 2023-04-19 2024-10-24 上海复宏汉霖生物技术股份有限公司 一种杂环取代的芳香化合物、其制备方法及用途
WO2025036382A1 (zh) 2023-08-14 2025-02-20 上海复宏汉霖生物医药有限公司 一种磺酰胺类化合物、其制备方法及用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781252A (zh) * 2012-11-08 2015-07-15 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的被烷基-酰胺取代的吡啶化合物
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104573A1 (en) * 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
HK1211024A1 (en) 2012-10-19 2016-05-13 霍夫曼-拉罗奇有限公司 Inhibitors of syk
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
CN110267964B (zh) 2016-12-13 2022-05-03 百时美施贵宝公司 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物
MX2020005210A (es) * 2017-11-21 2020-08-20 Bristol Myers Squibb Co Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781252A (zh) * 2012-11-08 2015-07-15 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的被烷基-酰胺取代的吡啶化合物
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物

Also Published As

Publication number Publication date
CN111315737A (zh) 2020-06-19
CL2020001338A1 (es) 2020-09-25
AR113895A1 (es) 2020-06-24
AU2018371010B2 (en) 2022-06-09
WO2019103952A1 (en) 2019-05-31
US20250304555A1 (en) 2025-10-02
MX2020005210A (es) 2020-08-20
NZ765438A (en) 2024-11-29
MY202167A (en) 2024-04-12
US11787779B2 (en) 2023-10-17
IL274816B2 (en) 2023-12-01
JP2023098942A (ja) 2023-07-11
KR20200089706A (ko) 2020-07-27
US11021462B2 (en) 2021-06-01
JP2021504443A (ja) 2021-02-15
IL274816A (en) 2020-07-30
JP7490107B2 (ja) 2024-05-24
JP7258903B2 (ja) 2023-04-17
US20210253554A1 (en) 2021-08-19
US20240002364A1 (en) 2024-01-04
AU2023255024B2 (en) 2025-05-01
CO2020006139A2 (es) 2020-05-29
ZA202003717B (en) 2022-01-26
AU2018371010A1 (en) 2020-07-02
IL274816B1 (en) 2023-08-01
TWI776994B (zh) 2022-09-11
US20190152948A1 (en) 2019-05-23
AU2023255024A1 (en) 2023-11-16
US12365667B2 (en) 2025-07-22
PE20211461A1 (es) 2021-08-05
AU2022228101A1 (en) 2022-09-29
CA3083122A1 (en) 2019-05-31
TW201925187A (zh) 2019-07-01
EP3713930A1 (en) 2020-09-30
AU2018371010C1 (en) 2024-09-26
KR102702228B1 (ko) 2024-09-02
SG11202004592TA (en) 2020-06-29
EA202091269A1 (ru) 2020-08-07
BR112020009606A2 (pt) 2020-11-03
AU2022228101B2 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
KR102858043B1 (ko) Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN106660960B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的烷基-酰胺-取代的吡啶化合物
EP4143180A1 (en) Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
JP7637626B2 (ja) アミド二置換のピリジンまたはピリダジン化合物
JP2021518389A (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
EP4337650A1 (en) Substituted heterocyclic compounds
CN117279906A (zh) 经取代的杂环化合物
CN114222744A (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
EA041710B1 (ru) Сульфон-, пиридин-, алкил-, амидзамещенные гетероарильные соединения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant